Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
News

News

Dato
08.01.2016
BONESUPPORT™ ANNOUNCES CERAMENT™ FOCUSED RESEARCH COLLABORATION WITH RIGSHOSPITALET, COPENHAGEN UNIVERSITY HOSPITAL

Rigshospitalet to evaluate CERAMENT™ platform for use in bone tumors


Dato
07.01.2016
PSIOXUS THERAPEUTICS APPOINTS DR PAOLO PAOLETTI AS CHAIRMAN OF THE BOARD
OXFORD, UK – 7 January 2016 – PsiOxus Therapeutics Ltd. (“PsiOxus”), the immuno-oncology company, has appointed Dr Paolo Paoletti, MD as Chairman of the Board.
Dato
07.01.2016
Takeda and Enterome Enter Strategic Drug Discovery Collaboration Focused on Microbiome Targets Across Multiple Gastrointestinal Disorders
Osaka, Japan, Paris, France and Boston, MA, USA, January 6, 2016 – Takeda Pharmaceutical Company Ltd. (TSE: 4502) and Enterome Bioscience SA (“Enterome”) today announced they have entered into a strategic drug discovery collaboration to research and develop potential new therapeutics directed at microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases (e.g. ulcerative colitis) and motility disorders (e.g. irritable bowel syndrome).
Dato
06.01.2016
BONESUPPORT™ ANNOUNCES POSITIVE DATA HIGHLIGHTING THE USE OF CERAMENT™|G IN THE MANAGEMENT OF OSTEOMYELITIS IN THE INFECTED DIABETIC FOOT
Two separate studies confirm efficacy of CERAMENT™|G, an antibiotic eluting bone substitute, as a new option in the surgical management of osteomyelitis in the infected diabetic foot.
Dato
06.01.2016
Vtesse, Inc. Announces FDA's Granting of Breakthrough Therapy Designation for VTS-270 in Niemann-Pick Type C1 Disease
GAITHERSBURG, Md., Jan. 6, 2016 /PRNewswire/ -- Vtesse, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial. 
Dato
06.01.2016
ACACIA PHARMA ANNOUNCES POSITIVE RESULTS FROM SECOND PIVOTAL PHASE 3 STUDY OF BAREMSIS™ (APD421) IN PREVENTION OF POST-OPERATIVE NAUSEA & VOMITING
Cambridge, UK – 5th January 2016: Acacia Pharma Group plc (“Acacia Pharma”), the supportive care company developing products for US and international markets, announces positive results from a Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) in combination with standard antiemetics for the prevention of post-operative nausea & vomiting (“PONV”) in high-risk patients. 
Dato
05.01.2016
BONESUPPORT™ ANNOUNCES POSITIVE DATA HIGHLIGHTING THE USE OF CERAMENT™|G IN THE MANAGEMENT OF OSTEOMYELITIS IN THE INFECTED DIABETIC FOOT

Two separate studies confirm efficacy of CERAMENT™|G, an antibiotic eluting bone substitute, as a new option in the surgical management of osteomyelitis in the infected diabetic foot. 

Lund, Sweden, (PRNEWSWIRE) January 5, 2016 – BONESUPPORT™, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, today announced data from two studies confirming the efficacy of the Company’s CERAMENT™ antibiotic eluting bone substitute technology as a step in the management of osteomyelitis (OM) in infected diabetic foot.   CERAMENT™|G, which releases Gentamicin, received CE-mark in 2013, and is the first approved antibiotic eluting bone substitute indicated to promote and protect bone healing in the management of bone infections.

Dato
11.12.2015
BONESUPPORT™ ANNOUNCES RESULTS OF CERAMENT™|BONE VOID FILLER PROSPECTIVE PILOT STUDY DEMONSTRATING COMPLETE BONE REMODELING IN BENIGN BONE TUMORS

93% of patients had full or partial cyst resolution at 12 months

• No post-operative infections reported during follow-up period

• No fractures reported during the follow-up period

Dato
11.12.2015
Veloxis announces change in management
Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Dr. William J. Polvino steps down as President and CEO after more than six years in the role.
Dato
08.12.2015
Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)

Ness Ziona, Israel – Dec 7, 2015 – Atox Bio, developer of immunomodulatory therapeutics for rapidly-progressing infectious diseases in critically ill patients, today announced that it has enrolled the first patient in its Phase 3 study to evaluate AB103 – the first-ever candidate developed for the treatment of Necrotizing Soft Tissue Infections (NSTIs), also known as ‘flesh eating bacteria’. The ACCUTE (AB103 Clinical Composite

endpoint StUdy in necrotizing soft Tissue InfEctions) study is conducted at approximately 40 centers in the U.S. and expects to enroll 290 patients who will receive around the clock coverage by highly experienced surgical teams and critical care support.

Forrige 1 2 3 4 5 6 7 8 9 10 Næste 10 Næste